Drugs / JNJ-17216498
last change Dec 2007 re-read 2 minutes ago

JNJ-17216498

targets HRH3 via inhibition

Developed for
narcolepsy
Investigated by
Alza Corporation

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00424931 Jan → Nov 2007 narcolepsy Alza Corporation Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as JNJ-17216498 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00424931
Action Inhibit “Histamine H3 receptor antagonist” CHEMBL3545030
Target HRH3 “Histamine H3 receptor antagonist” CHEMBL3545030